“…Based on the positive preclinical and phase-1 results, 7 , 8 , 9 treatment effect was assumed for 100 mg ASP1128 in the clinical setting. Reasons for an absence of this treatment effect on renal outcomes of ASP1128 can be related to issues with the compound (dosing, timing of treatment), the study (disbalance in confounding factors, population, and sample size), or both.…”